3-[3-(2-dimethylaminoethyl)ureido]-2-methyl-4-(3-nitrophenyl)-6-phenylpyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-[3-(2-dimethylaminoethyl)ureido]-2-methyl-4-(3-nitrophenyl)-6-phenylpyridine
• 英文别名: 1-[2-(dimethylamino)ethyl]-3-[2-methyl-4-(3-nitrophenyl)-6-phenylpyridin-3-yl]urea
• 化学式: C₂₃H₂₅N₅O₃
• 分子量: 419.483
• InChiKey: CNXFXIYKXKQSSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  二苯基膦叠氮化物 、 2-methyl-4-(3-nitrophenyl)-6-phenyl-3-pyridinecarboxylic acid 在 三乙胺 作用下， 以 水 、 乙酸乙酯 、 苯 为溶剂， 生成 3-[3-(2-dimethylaminoethyl)ureido]-2-methyl-4-(3-nitrophenyl)-6-phenylpyridine
  参考文献：
  名称：

  Morpholine containing pyridine compounds, compositions and use

  摘要：

  一种含氮杂环化合物，化学式为：##STR1##其中R.sup.1是较低的烷基，可选择地取代为羟基、卤素或杂环基，羧基、酯化羧基、羰基取代的羰基，可选择地取代为杂环(较低)烷基或较低烷基氨基(较低)烷基的含氮杂环羰基，可选择地取代为较低烷基的含氮杂环羰基，或可选择地取代为较低烷基氨基(较低)烷基的脲基，R.sup.3是氢或卤素；R.sup.2是取代硝基的苯基，X是.dbd.N--或##STR2##其中R.sup.4是较低的烷基或卤代(较低)烷基，或与R.sup.1共同形成可选择地取代为氧代和较低烷基氨基(较低)烷基的含氮杂环基；或R.sup.2是较低烷基，X是##STR3##其中R.sup.4是取代硝基的苯基；以及其药学上可接受的盐，其制备方法和包含相同的药物(例如抗高血压)组合物。

  公开号：

  US04857527A1

文献信息

• Di phenylpyridazine compounds, processes for the preparation thereof and
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04931453A1

  公开（公告）日：1990-06-05

  The invention relates to diphenylpyridazine compounds useful in the treatment of cerebrovascular disease, of the formula: ##STR1## wherein R.sup.1 is piperazinyl(lower)alkyl, carbamoyl substituted with piperazinyl(lower)alkyl, or piperazinylcarbonyl, in each of which a piperazinyl group may be substituted with lower alkyl, R.sup.2 is phenyl substituted with nitro, and R.sup.3 is hydrogen or halogen, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种用于治疗脑血管疾病的二苯吡嗪化合物，其化学式为：##STR1## 其中R.sup.1是哌嗪基（较低）烷基，用哌嗪基（较低）烷基取代的氨基甲酰基，或哌嗪基甲酰基，其中哌嗪基可以被较低烷基取代；R.sup.2是取代有硝基的苯基；R.sup.3是氢或卤素，或其药学上可接受的盐。
• Diphenylpyridine compounds, processes for the preparation thereof and
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04831030A1

  公开（公告）日：1989-05-16

  The invention relates to compounds for treatment of hypertension, and cardiovascular and cerebrovascular diseases, which compounds are of the formula: ##STR1## wherein R.sup.1 is piperazinyl(lower)alkyl, carbamoyl substituted with piperazinyl(lower)alkyl, or piperazinylcarbonyl, in each of which a piperazinyl group may be substituted with lower alkyl, and R.sup.3 is hydrogen or halogen; R.sup.2 is phenyl substituted with nitro, and R.sup.4 is lower alkyl or halo(lower)alkyl; or R.sup.2 is lower alkyl, and R.sup.4 is phenyl substitured with nitro; and a pharmaceutically acceptable salt thereof.

  本发明涉及用于治疗高血压、心血管和脑血管疾病的化合物，该化合物的化学式为：##STR1##其中R.sup.1是哌嗪基(较低)烷基、用哌嗪基(较低)烷基取代的氨基甲酰基或哌嗪基甲酰基，其中哌嗪基团可以用较低烷基取代，R.sup.3是氢或卤素；R.sup.2是取代有硝基的苯基，R.sup.4是较低烷基或卤代(较低)烷基；或者R.sup.2是较低烷基，R.sup.4是取代有硝基的苯基；以及其药学上可接受的盐。
• N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0228845A2

  公开（公告）日：1987-07-15

  An N-containing heterocyclic compound of the formula: I wherein R' is lower alkyl optionally substituted with hydroxy, halogen or a heterocyciic group, carboxy, esterified carboxy, carbamoyl optionally substituted with heterocyclic(lower)alkyl or lower alkylamino(lower)alkyl, N-containing heterocycliccarbonyl optionally substituted with lower alkyl, or ureido optionally substituted with lower alkylamino(lower)alkyl, and R3 is hydrogen or halogen; R2 is phenyl substituted with nitro, and X is = N-or in which R' is lower alkyl or halo (lower) alkyl, or is taken together with R' to form an N-containing heterocyclic group optionally substituted with oxo and lower alkylamino(lower)alkyl; or R2 is lower alkyl, and X is in which R4 is phenyl substituted with nitro; and a pharmaceutically acceptable salt thereof, processes for the preparation thereof and composition comprising the same.

  式中的含 N 杂环化合物：I 其中 R'是任选被羟基、卤素或杂环基取代的低级烷基、羧基、酯化羧基、任选被杂环（低级）烷基或低级烷基氨基（低级）烷基取代的氨基甲酰基、任选被低级烷基取代的含 N 杂环羰基或任选被低级烷基氨基（低级）烷基取代的脲基，以及 R3 是氢或卤素； R2 是被硝基取代的苯基，以及 X 是 = N-or 其中 R'是低级烷基或卤代（低级）烷基，或与 R'一起形成可选被氧代和低级烷基氨基（低级）烷基取代的含 N 杂环基团；或 R2 是低级烷基，且 X 是 其中 R4 是被硝基取代的苯基； 及其药学上可接受的盐、制备工艺和包含这些成分的组合物。
• Pyridine or pyridazine derivatives as cardio-protective agents and for the treatment of ischemic disease, and process for their preparation
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0311322A2

  公开（公告）日：1989-04-12

  A pharmaceutical composition as a cardioprotective agent or as a therapeutic agent for ischemic disease comprising a compound of the formula: wherein R1 is lower alkyl substituted with a heterocyclic group; carbamoyl substituted with heterocyclic(lower)alkyl or with lower alkylamino(lower)alkyl; N-containing heterocycliccarbonyl optionally substituted with lower alkyl; or ureido substituted with lower alkylamino(lower)alkyl; and R2 is phenyl substituted with nitro, and in which R3 is lower alkyl; or R2 is lower alkyl, and in which R3 is phenyl substituted with nitro; or its salt, as an active ingredient, in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient, and a process for the preparation of some of said compound or their salts

  一种作为心脏保护剂或缺血性疾病治疗剂的药物组合物，包含一种式化合物： 式中 R1 是被杂环基取代的低级烷基；被杂环（低级）烷基或低级烷基氨基（低级）烷基取代的氨基甲酰基；任选被低级烷基取代的含 N 杂环羰基；或被低级烷基氨基（低级）烷基取代的脲基；和 R2 是被硝基取代的苯基，以及 其中 R3 是低级烷基；或 R2 是低级烷基，且 其中 R3 是被硝基取代的苯基；或其盐，作为活性成分，与药学上可接受的、实质上无毒的载体或赋形剂一起使用，以及制备某些上述化合物或其盐的方法
• N-phenylpyri(mi)dine-N'-phenyl-urea derivatives, their preparation and their use as ACAT inhibitors
  申请人：NIHON NOHYAKU CO., LTD.

  公开号：EP0638557A1

  公开（公告）日：1995-02-15

  The present invention relates to a compound represented by the general formula (I): [wherein R¹ is a lower alkyl group, a lower cycloalkyl group, a lower alkoxy group, an aliphatic cyclic amino group which may be substituted by one or more lower alkyl groups, or a phenyl group which may be substituted by one or more halogen atoms, R² is a hydrogen atom or a lower alkyl group, R³ and R⁴, which may be the same or different, are hydrogen atoms, halogen atoms, lower alkyl groups, lower haloalkyl groups, lower alkoxy groups or lower alkylthio groups, R⁵, R⁶ and R⁷, which may be the same or different, are hydrogen atoms, halogen atoms, lower alkyl groups, lower haloalkyl groups, lower alkoxy groups, lower alkylthio groups or lower dialkylamino groups, and X is =N- or =CH-] or a pharmacologically acceptable salt thereof, which has inhibitory effect on acyl-CoA:cholesterol O-acyltransferase (ACAT), a process for producing said compound, and uses of said compound.

  本发明涉及通式 (I) 所代表的化合物： [其中 R¹ 是低级烷基、低级环烷基、低级烷氧基、可被一个或多个低级烷基取代的脂族环状氨基或可被一个或多个卤素原子取代的苯基，R² 是氢原子或低级烷基，R³ 和 R⁴ 可以相同或不同，是氢原子、卤素原子、低级烷基、低级卤代烷基、低级烷氧基或低级烷硫基、R⁵、R⁶和 R⁷可以相同或不同，它们是氢原子、卤素原子、低级烷基、低级卤代烷基、低级烷氧基、低级烷硫基或低级二烷基氨基，X 是 =N- 或 =CH-]或其药理学上可接受的盐，对酰基-CoA 具有抑制作用：胆固醇 O-酰基转移酶 (ACAT)具有抑制作用的化合物或其药理学可接受盐、生产所述化合物的工艺以及所述化合物的用途。